BioSpace News Archive

Immuneering Corporation announced the pricing of its underwritten offering of 2,727,273 shares of its Class A common stock at an offering price of $11.00 per share.

Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, supports the recent American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) position statement.

Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage biotechnology Company whose business is focused in the brain cancer space, announced today that the Protocol for the Phase 2 clinical trials was submitted to the FDA for review and approval.

Royal Philips announced an expansion of its initiative with the Institute for Medical Engineering and Science at the Massachusetts Institute of Technology to allow health care researchers access to a new critical care data set to help advance machine learning and artificial intelligence in healthcare.

The Insight Partners published latest research report on “Long Read Sequencing Market Trends Report, Size, Share, Growth Rate Forecast to 2028 - COVID-19 Impact and Global Analysis By Technology, Product, Application, End User and Geography,”

AB Science SA (Euronext - FR0010557264 - AB) today announced that the patent office of Japan has issued a Notice of Allowance (NOA) for a patent relating to methods of treating amyotrophic lateral sclerosis (ALS) with its lead compound masitinib (JP 2022037132A).

Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today presented preclinical data for two of its key clinical programs, HPN328 and HPN217, in three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting being held in Orlando, Fla., April 14-19, 2023.

MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, presented data at the American Association of Cancer Research (AACR) annual meeting.

Moleculin Biotech, Inc. today announced that positive preclinical data regarding the Company’s next-generation anthracycline, Annamycin, was presented at the American Association for Cancer Research (AACR) Annual Meeting.

Kerecis announced that, over the past year, 63 million more Americans became eligible for insurance coverage for the company’s fish-skin treatments, an increase of more than 70%.